罗莫佐单抗安全性的全球“有条件”保证：关于日本不良心血管事件独特性的国际共识 - Suppr

Suppr

超能文献

Global 'Conditional' Assurance of Romosozumab Safety: International Consensus on the Uniqueness of Adverse Cardiovascular Events in Japan.

作者信息

Kawaguchi Hiroshi

机构信息

Orthopaedics, Nadogaya Hospital, Shin-Kashiwa, Kashiwa, Chiba, 277-0084, Japan.

出版信息

Calcif Tissue Int. 2024 Oct;115(4):455-458. doi: 10.1007/s00223-024-01267-4. Epub 2024 Jul 30.

DOI:10.1007/s00223-024-01267-4

PMID:39079979

Abstract

摘要

相似文献

Global 'Conditional' Assurance of Romosozumab Safety: International Consensus on the Uniqueness of Adverse Cardiovascular Events in Japan.罗莫佐单抗安全性的全球“有条件”保证：关于日本不良心血管事件独特性的国际共识

Calcif Tissue Int. 2024 Oct;115(4):455-458. doi: 10.1007/s00223-024-01267-4. Epub 2024 Jul 30.

A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.一项评价罗莫佐单抗治疗男性骨质疏松症的疗效和安全性的 III 期随机安慰剂对照试验。

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3183-3193. doi: 10.1210/jc.2017-02163.

Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk.罗莫佐单抗：疗效、安全性和心血管风险的评价。

Curr Osteoporos Rep. 2021 Feb;19(1):15-22. doi: 10.1007/s11914-020-00652-w. Epub 2021 Jan 7.

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。

N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.

Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.罗莫佐单抗治疗骨质疏松症患者的早期临床效果、安全性及骨标志物的合理选择：一项 6 个月的研究。

Osteoporos Int. 2021 Apr;32(4):653-661. doi: 10.1007/s00198-020-05639-y. Epub 2020 Sep 26.

Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.地舒单抗或罗莫佐单抗治疗与原发性骨质疏松症患者心血管事件风险：系统评价和荟萃分析。

Bone. 2020 Jan;130:115121. doi: 10.1016/j.bone.2019.115121. Epub 2019 Oct 31.

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.罗莫佐单抗增加绝经后骨质疏松日本女性的骨密度：一项 2 期研究。

Bone. 2017 Oct;103:209-215. doi: 10.1016/j.bone.2017.07.005. Epub 2017 Jul 5.

Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate.罗莫佐单抗的心血管结局和阿仑膦酸钠的保护作用。

Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1343-1350. doi: 10.1161/ATVBAHA.119.312371. Epub 2019 May 23.

Romosozumab: First Global Approval.罗莫索单抗：全球首次获批。

Drugs. 2019 Mar;79(4):471-476. doi: 10.1007/s40265-019-01072-6.

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.罗莫佐单抗治疗女性骨质疏松症：疗效、安全性和心血管风险。

Womens Health (Lond). 2022 Jan-Dec;18:17455057221125577. doi: 10.1177/17455057221125577.

引用本文的文献

Misaligned cardiovascular safety warnings for romosozumab in Japan.日本关于罗莫索单抗的心血管安全警告不一致。

J Bone Miner Metab. 2025 May;43(3):315-316. doi: 10.1007/s00774-025-01593-z. Epub 2025 Feb 24.

Revisiting the safety of romosozumab in Japan: the need for clear contraindications for patients with cardiovascular risk.

Osteoporos Int. 2025 Mar;36(3):563-564. doi: 10.1007/s00198-024-07347-3. Epub 2025 Jan 8.

Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment.硬化素与心血管风险：评估罗莫佐单抗治疗骨质疏松症时的心血管安全性

Biomedicines. 2024 Dec 18;12(12):2880. doi: 10.3390/biomedicines12122880.

本文引用的文献

Response to Letter to the Editor From Kawaguchi: "Cardiovascular Safety of Romosozumab vs PTH Analogs for Osteoporosis Treatment: A Propensity Score Matched Cohort Study".对川口致编辑信的回复：“罗莫索单抗与甲状旁腺激素类似物治疗骨质疏松症的心血管安全性：一项倾向评分匹配队列研究”

J Clin Endocrinol Metab. 2024 Sep 16;109(10):e1978-e1979. doi: 10.1210/clinem/dgae348.

Reduced Sclerostin Expression in Human Atherosclerotic Plaques Links to Ischemic Stroke.人类动脉粥样硬化斑块中硬化素表达降低与缺血性中风相关。

J Am Heart Assoc. 2024 May 21;13(10):e033038. doi: 10.1161/JAHA.123.033038. Epub 2024 May 10.

Cardiovascular Safety and Romosozumab-The Plot Thickens.心血管安全性与罗莫索单抗——情节愈发复杂

J Clin Endocrinol Metab. 2024 Dec 18;110(1):e190-e191. doi: 10.1210/clinem/dgae313.

Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells.骨硬化蛋白通过减少人血管平滑肌细胞中的钙沉积、增殖和凋亡发挥心脏保护作用。

Cardiovasc Diabetol. 2023 Nov 2;22(1):301. doi: 10.1186/s12933-023-02043-8.

Evaluation of Risk of Cardiac or Cerebrovascular Events in Romosozumab Users Focusing on Comorbidities: Analysis of the Japanese Adverse Drug Event Report Database.关注合并症评估使用罗莫索单抗患者发生心脑血管事件的风险：日本药品不良事件报告数据库分析

J Pharm Technol. 2023 Feb;39(1):23-28. doi: 10.1177/87551225221144960. Epub 2022 Dec 28.

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS).罗莫单抗的心血管安全性概况：对美国食品药品监督管理局不良事件报告系统（FAERS）的药物警戒分析

J Clin Med. 2021 Apr 13;10(8):1660. doi: 10.3390/jcm10081660.

Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk.罗莫佐单抗：疗效、安全性和心血管风险的评价。

Curr Osteoporos Rep. 2021 Feb;19(1):15-22. doi: 10.1007/s11914-020-00652-w. Epub 2021 Jan 7.

Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide.日本患者使用罗莫索单抗的严重不良事件：全球范围内需要明确制定禁忌证

J Bone Miner Res. 2020 May;35(5):994-995. doi: 10.1002/jbmr.4001. Epub 2020 Apr 1.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3183-3193. doi: 10.1210/jc.2017-02163.

Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes.骨硬化蛋白通过调节脂肪细胞的分解代谢和合成代谢来影响身体成分。

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11238-E11247. doi: 10.1073/pnas.1707876115. Epub 2017 Dec 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验